Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study

Giuseppe Giaccone, Marielle Gallegos Ruiz, Thierry Le Chevalier, Nick Thatcher, Egbert Smit, Jose Antonio Rodriguez, Pasi Janne, Dalila Oulid-Aissa, Jean-Charles Soria, Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study Clinical Cancer Research. ,vol. 12, pp. 6049- 6055 ,(2006) , 10.1158/1078-0432.CCR-06-0260

Federico Cappuzzo, Tudor Ciuleanu, Lilia Stelmakh, Saulius Cicenas, Aleksandra Szczésna, Erzsébet Juhász, Emilio Esteban, Olivier Molinier, Wolfram Brugger, Ivan Melezínek, Gaëlle Klingelschmitt, Barbara Klughammer, Giuseppe Giaccone, Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncology. ,vol. 11, pp. 521- 529 ,(2010) , 10.1016/S1470-2045(10)70112-1

David M. Jackman, Beow Y. Yeap, Neal I. Lindeman, Panos Fidias, Michael S. Rabin, Jennifer Temel, Arthur T. Skarin, Matthew Meyerson, Alison J. Holmes, Ana M. Borras, Boris Freidlin, Patricia A. Ostler, Joan Lucca, Thomas J. Lynch, Bruce E. Johnson, Pasi A. Jänne, Phase II Clinical Trial of Chemotherapy-Naïve Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 25, pp. 760- 766 ,(2007) , 10.1200/JCO.2006.07.5754

Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Enriqueta Felip, Ramon Palmero, Ramon Garcia-Gomez, Cinta Pallares, Jose Miguel Sanchez, Rut Porta, Manuel Cobo, Pilar Garrido, Flavia Longo, Teresa Moran, Amelia Insa, Filippo De Marinis, Romain Corre, Isabel Bover, Alfonso Illiano, Eric Dansin, Javier De Castro, Michele Milella, Noemi Reguart, Giuseppe Altavilla, Ulpiano Jimenez, Mariano Provencio, Miguel Angel Moreno, Josefa Terrasa, Jose Muñoz-Langa, Javier Valdivia, Dolores Isla, Manuel Domine, Olivier Molinier, Julien Mazieres, Nathalie Baize, Rosario Garcia-Campelo, Gilles Robinet, Delvys Rodriguez-Abreu, Guillermo Lopez-Vivanco, Vittorio Gebbia, Lioba Ferrera-Delgado, Pierre Bombaron, Reyes Bernabe, Alessandra Bearz, Angel Artal, Enrico Cortesi, Christian Rolfo, Maria Sanchez-Ronco, Ana Drozdowskyj, Cristina Queralt, Itziar de Aguirre, Jose Luis Ramirez, Jose Javier Sanchez, Miguel Angel Molina, Miquel Taron, Luis Paz-Ares, None, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology. ,vol. 13, pp. 239- 246 ,(2012) , 10.1016/S1470-2045(11)70393-X

Cesare Gridelli, Fortunato Ciardiello, Ciro Gallo, Ronald Feld, Charles Butts, Vittorio Gebbia, Paolo Maione, Floriana Morgillo, Giovenzio Genestreti, Adolfo Favaretto, Natasha Leighl, Rafal Wierzbicki, Saverio Cinieri, Yasmin Alam, Salvatore Siena, Giampaolo Tortora, Raffaella Felletti, Ferdinando Riccardi, Gianfranco Mancuso, Antonio Rossi, Flavia Cantile, Ming-Sound Tsao, Mauro Saieg, Gilda da Cunha Santos, Maria Carmela Piccirillo, Massimo Di Maio, Alessandro Morabito, Francesco Perrone, First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial Journal of Clinical Oncology. ,vol. 30, pp. 3002- 3011 ,(2012) , 10.1200/JCO.2011.41.2056

Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, Shunichi Negoro, Isamu Okamoto, Junji Tsurutani, Takashi Seto, Miyako Satouchi, Hirohito Tada, Tomonori Hirashima, Kazuhiro Asami, Nobuyuki Katakami, Minoru Takada, Hiroshige Yoshioka, Kazuhiko Shibata, Shinzoh Kudoh, Eiji Shimizu, Hiroshi Saito, Shinichi Toyooka, Kazuhiko Nakagawa, Masahiro Fukuoka, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncology. ,vol. 11, pp. 121- 128 ,(2010) , 10.1016/S1470-2045(09)70364-X

Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, Shunichi Sugawara, Satoshi Oizumi, Hiroshi Isobe, Akihiko Gemma, Masao Harada, Hirohisa Yoshizawa, Ichiro Kinoshita, Yuka Fujita, Shoji Okinaga, Haruto Hirano, Kozo Yoshimori, Toshiyuki Harada, Takashi Ogura, Masahiro Ando, Hitoshi Miyazawa, Tomoaki Tanaka, Yasuo Saijo, Koichi Hagiwara, Satoshi Morita, Toshihiro Nukiwa, Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR The New England Journal of Medicine. ,vol. 362, pp. 2380- 2388 ,(2010) , 10.1056/NEJMOA0909530

Frances A. Shepherd, José Rodrigues Pereira, Tudor Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel Campos, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins, Maximiliano van Kooten, Mircea Dediu, Brian Findlay, Dongsheng Tu, Dianne Johnston, Andrea Bezjak, Gary Clark, Pedro Santabárbara, Lesley Seymour, Erlotinib in previously treated non-small-cell lung cancer. The New England Journal of Medicine. ,vol. 353, pp. 123- 132 ,(2005) , 10.1056/NEJMOA050753

Ji-Youn Han, Keunchil Park, Sang-We Kim, Dae Ho Lee, Hyae Young Kim, Heung Tae Kim, Myung Ju Ahn, Tak Yun, Jin Seok Ahn, Cheolwon Suh, Jung-Shin Lee, Sung Jin Yoon, Jong Hee Han, Jae Won Lee, Sook Jung Jo, Jin Soo Lee, First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung Journal of Clinical Oncology. ,vol. 30, pp. 1122- 1128 ,(2012) , 10.1200/JCO.2011.36.8456

Caicun Zhou, Yi-Long Wu, Gongyan Chen, Jifeng Feng, Xiao-Qing Liu, Changli Wang, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren, Shun Lu, Li Zhang, Chengping Hu, Chunhong Hu, Yi Luo, Lei Chen, Ming Ye, Jianan Huang, Xiuyi Zhi, Yiping Zhang, Qingyu Xiu, Jun Ma, Li Zhang, Changxuan You, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncology. ,vol. 12, pp. 735- 742 ,(2011) , 10.1016/S1470-2045(11)70184-X